TB10mg + BPC-157 10mg + GHK 50mg + KPV 10mg
Overview
This advanced peptide blend combines four powerful research peptides—TB-500 (Thymosin Beta-4 fragment), BPC-157, GHK-Cu, and KPV—to create a synergistic formula studied for tissue repair, anti-inflammatory effects, skin rejuvenation, and immune modulation. It is designed for laboratory research purposes only and is not approved for human consumption.
Key Components
- TB-500 (Thymosin Beta-4 fragment, 10mg)
- Promotes cell migration and angiogenesis.
- Studied for accelerating recovery from injuries and reducing inflammation.
- BPC-157 (10mg)
- Synthetic peptide derived from gastric proteins.
- Investigated for tendon, ligament, and gut tissue healing.
- May reduce inflammation and protect organs under stress.
- GHK-Cu (50mg)
- Copper-binding peptide naturally found in plasma.
- Stimulates collagen production, improves skin elasticity, and reduces wrinkles.
- Studied for hair growth stimulation and wound healing.
- KPV (10mg)
- A tripeptide fragment of alpha-MSH.
- Known for strong anti-inflammatory and antimicrobial properties.
- Studied for gut health, immune modulation, and reducing inflammatory conditions.
Benefits in Research Context
- Tissue Repair & Recovery: Supports healing of muscles, tendons, ligaments, and skin.
- Anti-Inflammatory Effects: KPV and BPC-157 reduce inflammation and promote faster recovery.
- Skin & Hair Rejuvenation: GHK-Cu enhances collagen synthesis and hair follicle stimulation.
- Immune Support: KPV contributes to immune regulation and antimicrobial defense.
- Synergistic Action: Combination of peptides provides broader regenerative potential than single compounds.
Risks & Considerations
- Research Use Only: Not FDA-approved for human consumption; intended strictly for laboratory studies.
- Potential Side Effects: Limited data; nausea, dizziness, or injection site irritation have been reported in peptide studies.
- Long-Term Safety Unknown: More clinical trials are needed to confirm efficacy and safety.


Reviews
There are no reviews yet.